Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development

 

The purpose of this program is to coordinate the acceleration of countermeasure and product advanced research and development by(A) facilitating collaboration between the Department of Health and Human Services and other Federal agencies, relevant industries, academia, and other persons, with respect to such advanced research and development; (B) promoting countermeasure and product advanced research and development; (C) facilitating contacts between interested persons and the offices or employees authorized by the Secretary to advise such persons regarding requirements under the Federal Food, Drug, and Cosmetic Act and under section 351 of the Public Health Service Act; and (D) promoting innovation to reduce the time and cost of countermeasure and product advanced research and development. The Public Health Service Act at 42 U.S.C. 247d-6a defines a qualified countermeasure as a drug (as that term is defined by section 321(g)(1) of title 21), biological product (as that term is defined by section 262(i) of this title), or device (as that term is defined by section 321(h) of title 21), that the Secretary determines to be a priority (consistent with sections 182(2) and 184(a) of title 6) to - (i) diagnose, mitigate, prevent, or treat harm from any biological agent (including organisms that cause an infectious disease) or toxin, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security; or (ii) diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device that is used as described in this subparagraph

Active 93.360 Office of The Secretary, Department of Health and Human Services B - Project Grants Not applicable. Public Health Service Act, Title III, Section 319L
Consolidated Appropriations Act, 2010, Division D, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010 All types of entities are eligible, including highly qualified foreign nationals outside the United States either alone or in collaboration with American participants when such transactions may inure to the benefit of the American people. Applicants should review the individual funding opportunity announcements issued under this CFDA program. All individuals including at-risk individuals such as children, pregnant women, elderly, and others at-risk who may be given special priority. Applicants should review the individual funding opportunity announcements issued under this CFDA program for any credentials or certifications that must be submitted prior to or simultaneous with submission of an application package. Preapplication coordination is not applicable. 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. Grant applications and required forms for this program can be obtained through Grants.gov - FIND, http://www.grants.gov/. Applicants should visit Grants.gov - FIND for the funding opportunity announcement and Grants.gov - APPLY to download application materials to complete and submit their applications in accordance with the funding opportunity announcement (FOA). Applications that successfully proceed through initial screening (as outlined in the funding opportunity announcement) will be objectively reviewed based upon the review criteria specified in the FOA. Applications selected for funding will be processed and the applicant notified in writing through the issuance of a Notice of Award from the Office of the Assistant Secretary for Preparedness and Response. September 30, 2018 Applicable deadlines and due dates are specified in each funding opportunity announcement. From 90 to 120 days. Not applicable. Not applicable. Discretionary awards are subject to objective review. Reviewers will individually evaluate and score applications based upon the review criteria specified in the funding opportunity announcement. Scored applications will be ordinally ranked. The highest ranked applications will receive priority consideration for award within available funding. Support international in-country and domestic advanced development and industrialization of human pandemic influenza vaccine. Support activities related to the mitigation of the global shortage of influenza vaccines through awards and sub-awards to developing countries with the potential and capacity to manufacture various influenza vaccines. Performance Reports: Performance monitoring of awardees is completed by BARDA program staff. In accordance with the provisions of 2 CFR 200, Subpart F - Audit Requirements, nonfederal entities that expend financial assistance of $750,000 or more in Federal awards will have a single or a program-specific audit conducted for that year. Non-Federal entities that expend less than $750,000 a year in Federal awards are exempt from Federal audit requirements for that year, except as noted in 2 CFR 200.503 A-133 Records must be kept available for 3 years after submission of the final expenditure report. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. Project periods are limited up to 60 months. Budget periods are limited up to 12 months. Awardee is issued a Notice of Award, a legal document that informs the awardee that a grant award has been made. Awardee may draw down funds in advance of the incursion of an expenditure (up to three days) from the Payment Management System. None/Not specified. Rick A. Bright
330 Independence Ave SW, Room G-640, Washington, District of Columbia 20201
Washington, DC 20201 US
Rick.Bright@hhs.gov
Phone: 202-260-8535 https://www.medicalcountermeasures.gov/ 75-0140-0-1-551 (Project Grants (Cooperative Agreements)) FY 19$40,000,000.00; FY 20 est $3,000,000.00; FY 21 est $3,000,000.00; FY 18$55,000,000.00; FY 17$55,000,000.00; FY 16$30,000,000.00; - $30,000,000 to $55,000,000 Public Law 109-417, 45 CFR 92, 45 CFR 74, 45 CFR 46, 2 CFR, HHS Grants Policy Statement found at http://www.hhs.gov/asrt/og/grantinformation/hhsgps107.pdf